| Literature DB >> 19622164 |
Johannes Wollbold1, René Huber, Dirk Pohlers, Dirk Koczan, Reinhard Guthke, Raimund W Kinne, Ulrike Gausmann.
Abstract
BACKGROUND: Due to the rapid data accumulation on pathogenesis and progression of chronic inflammation, there is an increasing demand for approaches to analyse the underlying regulatory networks. For example, rheumatoid arthritis (RA) is a chronic inflammatory disease, characterised by joint destruction and perpetuated by activated synovial fibroblasts (SFB). These abnormally express and/or secrete pro-inflammatory cytokines, collagens causing joint fibrosis, or tissue-degrading enzymes resulting in destruction of the extra-cellular matrix (ECM).We applied three methods to analyse ECM regulation: data discretisation to filter out noise and to reduce complexity, Boolean network construction to implement logic relationships, and formal concept analysis (FCA) for the formation of minimal, but complete rule sets from the data.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19622164 PMCID: PMC2734845 DOI: 10.1186/1752-0509-3-77
Source DB: PubMed Journal: BMC Syst Biol ISSN: 1752-0509
List of genes used in this analysis.
| Type I collagen alpha 1 chain | Structural component | Cartilage and connective tissue collagen | |
| Type I collagen alpha 2 chain | Structural component | Cartilage and connective tissue collagen | |
| Matrix metalloprotease 1 (interstitial collagenase) | Protease | Cleavage of collagen I, II, and III | |
| Matrix metalloprotease 3 (stromelysin 1) | Protease | ECM component degradation | |
| Matrix metalloprotease 9 (gelatinase B) | Protease | Cleavage of collagen IV and V | |
| Matrix metalloprotease 13 (collagenase 3) | Protease | Cleavage of collagen I and III | |
| Tissue inhibitor of metalloprotease 1 (collagenase inhibitor) | Protease inhibitor | Inhibits matrix metalloproteases, and others | |
| v-ets erythroblastosis virus E26 oncogene homolog 1 | Transcription factor | Erythroblast and fibroblast transformation | |
| v-fos FBJ murine osteosarcoma viral oncogene homolog | Component of AP-1 | Regulator of proliferation, differentiation, and transformation | |
| v-jun avian sarcoma virus 17 oncogene homolog | Component of AP-1 | Regulator of proliferation, differentiation, and transformation | |
| jun B proto-oncogene | Component of AP-1 | Regulator of proliferation, differentiation, and transformation | |
| jun D proto-oncogene | Component of AP-1 | Regulator of proliferation, differentiation, and transformation | |
| Subunit 1 of nuclear factor kappa-B | Component of NF-κB | Involved in many biological processes | |
| SMA- and MAD-related protein 3 | Transcriptional modulator | Mediator of signal transduction by TGFβ1 (RSMAD) | |
| SMA- and MAD-related protein 4 | Transcriptional modulator | Mediator of signal transduction by TGFβ1 (CoSMAD) | |
| SMA- and MAD-related protein 7 | Transcriptional modulator | Antagonist of signalling by TGFβ1 (ISMAD) | |
| Tumour necrosis factor alpha | Cytokine | Proinflammatory role | |
| Transforming growth factor beta 1 | Growth factor | Involved in proliferation and differentiation |
Figure 1Overview of the ECM network in hierarchical order. Regulatory effects via TF s are shown as continuous lines, others as indirect effects as dashed lines. Inhibition is marked by a red T-arrow, induction is illustrated by black arrows. The external signals TGFβ1 and TNFα are shown as light grey circles, the internal SMAD signalling molecules as dark grey squares, TFs are depicted as black (AP-1 components) or white squares, and the target genes are shown as white octagons. This picture was generated using Cytoscape 2.6.0.
Boolean functions based on literature information.
| 1 | COL1A1.out | = (TGFB1 OR FOS OR JUN) AND NOT (TNF AND (NFKB1 OR ETS1)) |
| 2 | COL1A2.out | = ((TGFB1 AND JUND) OR JUN) AND NOT (TNF AND (NFKB1 OR ETS1)) |
| 3 | ETS1.out | = ((TNF AND (ETS1 OR JUN)) OR FOS) AND NOT SMAD4 |
| 4 | FOS.out | = (TGFB1 OR (TNF AND NFKB1)) AND NOT (JUN AND FOS) |
| 5 | JUN.out | = (TNF AND JUN) OR SMAD4 |
| 6 | JUNB.out | = (TGFB1 AND NFKB1 AND SMAD4) OR (TNF AND NFKB1) |
| 7 | JUND.out | = (TGFB1 OR TNF) AND JUND AND NOT FOS |
| 8 | MMP1.out | = ((TNF AND (ETS1 OR NFKB1)) OR FOS OR JUND) AND NOT TGFB1 |
| 9 | MMP3.out | = (TNF AND (ETS1 OR JUN OR NFKB1)) OR FOS OR TGFB1 |
| 10 | MMP9.out | = TNF AND (ETS1 OR NFKB1) |
| 11 | MMP13.out | = (TNF AND (JUN OR NFKB1)) OR FOS OR (TGFB1 AND SMAD4) |
| 12 | NFKB1.out | = (TNF AND (ETS1 OR NFKB1)) OR TGFB1 |
| 13 | SMAD4.out | = TGFB1 |
| 14 | SMAD7.out | = ((TGFB1 AND SMAD4) OR FOS OR JUN) AND NOT (TNF AND NFKB1) |
| 15 | TIMP1.out | = (TGFB1 AND SMAD4) OR (TNF AND (JUN OR JUNB OR JUND OR NFKB1)) OR FOS |
| 16 | TGFB1.out | = FOS OR JUND |
| 17 | TNF.out | = TNF AND (ETS1 OR JUN OR NFKB1) |
Revised Boolean functions for the simulation of TGFβ1 stimulation.
| COL1A1.out | = TGFB1 OR FOS OR JUN | * | |
| COL1A2.out | = (TGFB1 AND JUND) OR JUN | * | |
| ETS1.out | = FOS | * | |
| 4 | FOS.out | = (TGFB1 OR (TNF AND NFKB1)) AND NOT (JUN AND FOS) | |
| 5 | JUN.out | = (TNF AND JUN) OR ( | |
| 6 | JUNB.out | = (TGFB1 AND NFKB1 AND SMAD4 | |
| 7 | JUND.out | = TGFB1 OR TNF | |
| MMP1.out | = JUND AND NOT (TGFB1 | * | |
| MMP3.out | = (TNF AND ((ETS1 | ||
| 10 | MMP9.out | = TNF AND ETS1 | |
| MMP13.out | = (TNF AND (JUN OR NFKB1)) OR FOS | ||
| NFKB1.out | = TNF | * | |
| 13 | SMAD4.out | = TGFB1 | * |
| SMAD7.out | = (TGFB1 AND SMAD4 | * | |
| 15 | TIMP1.out | = (TGFB1 AND SMAD4 | |
| 16 | TGFB1.out | = FOS OR JUND | |
| 17 | TNF.out | = TNF AND ((ETS1 | |
| Inactivation rule | |||
Rows marked by an asterisk indicate differences of the functions for TGFβ1 and TNFα stimulation, changes to Table 2 are italicised and printed in bold. Function numbers in bold indicate omitted (1, 2, 3, 8, 9, 11, 12, 14) or inserted (18) terms.
Revised Boolean functions for the simulation of TGFα stimulation.
| COL1A1.out | = (FOS OR JUN) AND NOT (TNF AND ETS1 | * | |
| COL1A2.out | = JUN AND NOT (TNF AND ETS1 | * | |
| 3 | ETS1.out | = (TNF AND (ETS1 OR JUN)) OR FOS | * |
| 4 | FOS.out | = (TGFB1 OR (TNF AND NFKB1)) AND NOT (JUN AND FOS) | |
| 5 | JUN.out | = (TNF AND JUN) OR ( | |
| 6 | JUNB.out | = (TGFB1 AND NFKB1 AND SMAD4 | |
| 7 | JUND.out | = TGFB1 OR TNF | |
| MMP1.out | = (TNF AND ETS1 | * | |
| MMP3.out | = (TNF AND ((ETS1 | ||
| 10 | MMP9.out | = TNF AND ETS1 | |
| MMP13.out | = (TNF AND (JUN OR NFKB1)) OR FOS | ||
| NFKB1.out | = TNF AND (ETS1 OR NFKB1) | * | |
| SMAD4.out | = | * | |
| SMAD7.out | = (FOS OR JUN) AND NOT (TNF AND NFKB1) | * | |
| 15 | TIMP1.out | = (TGFB1 AND SMAD4 | |
| 16 | TGFB1.out | = FOS OR JUND | |
| 17 | TNF.out | = TNF AND ((ETS1 | |
| Inactivation rule | |||
Rows marked by an asterisk indicate differences of the functions for TGFβ1 and TNFα stimulation. changes to Table 2 are italicised and printed in bold. Function numbers in bold indicate omitted (1, 2, 8, 9, 11, 12, 13, 14) or inserted (18) terms.
Clinical characteristics of the patients at the time of synovectomy/sampling.
| Patients (n) | 3 | 3 | |
| Sample name | RA1, RA2, RA3, | OA1, OA2, OA3 | |
| Gender (female/male) | 3/0 | 1/2 | |
| Age (years ± SEM) | 62.4 ± 2.9 | 58.7 ± 2.0 | |
| Disease duration (years ± SEM) | 11.5 ± 0.5 | 4.4 ± 0.6 | |
| Rheumatic factor (positive/negative) | 3/0 | 0/3 | |
| ESR1 (mm/h ± SEM) | 26.7 ± 6.2 | 20.0 ± 4.0 | |
| CRP2 (mg/l ± SEM) | 38.1 ± 7.2 | 13.2 ± 2.9 | |
| ARA3 – Criteria for RA (n ± SEM) | 6.0 ± 1.1 | 0.3 ± 0.1 | |
| Concomitant | MTX4 (n) | 1 | 0 |
| medication | NSAIDs5 (n) | 3 | 3 |
1 Erythrocyte sedimentation rate
2 C-reactive protein, normal range: < 5 mg/l
3 American Rheumatism Association (now: American College of Rheumatology)
4 Methotrexate
5 Non steroidal anti-inflammatory drugs
Figure 2Gene expression time courses following TGFβ1 or TNFα treatment. COL1A1 (A), JUNB (B), and SMAD7 (C) gene expression in response to TGFβ1 treatment (upper row); TNFα response (lower row) of NFKB1 (D), MMP1 (E), and SMAD7 (F). The average time course is shown as light red curve without symbols, the data for individual samples are depicted in other colours (OA1: blue, filled symbol; OA2: red, filled symbol; OA3: green, filled symbol; RA1: purple, filled symbol; RA2: blue, open symbol; RA3: yellow, open symbol). The time courses and the values calculated from the microarray experiments for all analysed genes are included in additional file 4.
Example for the observed transition context K. The rows represent the transitions from state n to the state (n+1) of sample OA1 following TNFα stimulation.
| on | off | off | on | off | ... | on | on | on | on | on | ... | |
| on | off | off | on | off | ... | off | on | on | on | on | ... | |
| on | off | off | on | off | ... | off | off | off | on | on | ... | |
| on | off | off | on | off | ... | on | off | off | on | on | ... | |
| on | on | on | on | on | ... | off | on | on | on | on | ... | |
| ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... |